What it is
Epitalon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), molecular formula C₁₄H₂₂N₄O₉, molecular weight 390.35 Da, CAS 307297-39-8, PubChem CID 219042. It was synthesized at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues in the early 1990s as the putative active tetrapeptide within Epithalamin, a bovine pineal polypeptide complex used in the Russian geriatric-medicine tradition. Epitalon was identified as the shared minimal bioactive sequence between pineal gland and retinal peptide preparations — a finding the Khavinson group attributes to the common embryonal origin of the two tissues — and was later reported (2017) to be detectable in physiological human pineal extracts, reclassifying it as an endogenous peptide rather than a purely synthetic analogue. Epitalon is not a currently approved finished drug product in any major jurisdiction and is sold in the United States solely as a research chemical.
How it works
- 01
hTERT promoter activation and telomerase reactivation (cell culture)
Khavinson, Bondarev & Butyugov (2003, Bull Exp Biol Med) reported that addition of Epitalon to cultures of telomerase-negative human fetal fibroblasts induced expression of the hTERT catalytic subunit, reconstituted telomerase enzymatic activity, and produced measurable telomere elongation. The proposed mechanism is direct interaction with ATTTC-like motifs in the hTERT promoter — a sequence-specific DNA-binding hypothesis advanced by the Khavinson group based on computational docking and correlation between motif occurrence and bioactivity. This proposed DNA-binding mechanism has not been confirmed by an independent Western lab using radioligand binding, EMSA, or ChIP-seq.
- 02
Bypassing the Hayflick limit and replicative-senescence extension
In the same 2003 fibroblast program, Epitalon-treated cells divided beyond 44 passages compared with 34 passages in untreated controls — a reported extension of replicative capacity consistent with telomerase reactivation. No independent lab has reproduced this specific fibroblast Hayflick-limit extension in peer-reviewed Western literature, and the finding remains the single most-cited but least-replicated mechanistic claim associated with Epitalon.
- 03
Dual-pathway telomere maintenance: telomerase-dependent in normal cells, ALT in cancer cells
Bagherpour Doun et al. (2025, Biogerontology) treated breast-cancer lines 21NT and BT474 and normal epithelial/fibroblast cells with 0.5 and 1 µg/mL Epitalon for 4 days. hTERT expression was reported as upregulated 12-fold in 21NT at 1 µg/mL and 5-fold in BT474 at 0.5 µg/mL, with qPCR and immunofluorescence used to demonstrate dose-dependent telomere extension. The authors describe two distinct pathways: telomerase-dependent lengthening in normal cells (requiring approximately 3 weeks of incubation) and Alternative Lengthening of Telomeres (ALT) activation in cancer cells within 4 days. The ALT-in-cancer finding is biologically important — it directly raises the question of whether Epitalon could accelerate telomere maintenance in pre-malignant or malignant populations in vivo. No controlled human study has addressed this oncologic safety question.
- 04
Heterochromatin decondensation and epigenetic modulation (aged lymphocytes)
Khavinson-group cytogenetic work (reviewed in Khavinson 2020, Int J Mol Sci) reported that Epitalon induced decondensation of pericentromeric heterochromatin in cultured lymphocytes from donors aged 76–80, interpreted as partial restoration of a 'younger' chromatin accessibility pattern. The study framework relies on morphological chromatin scoring rather than ATAC-seq or single-cell epigenomic readouts, and has not been replicated with modern chromatin-accessibility methods.
- 05
Pineal-gland melatonin biosynthesis (AANAT / pCREB)
Khavinson et al. (2012, Bull Exp Biol Med) showed in rat pinealocyte culture that Epitalon increased AANAT (arylalkylamine-N-acetyltransferase) and pCREB protein levels and raised melatonin output in the medium, with norepinephrine co-administration producing synergistic induction. Non-human-primate work from the same group reported restoration of nocturnal melatonin peaks in aged monkeys. This is the mechanistic basis for the 'circadian-rhythm normalization' outcome. Human-subject data with formal salivary or plasma melatonin measurement under placebo control is absent.
- 06
Mitochondrial preservation and ROS attenuation
Gao et al. (2022, Aging) reported that 0.1 mM Epitalon in vitro reduced intracellular ROS, preserved spindle morphology, increased mitochondrial membrane potential (ΔΨm via JC-1), and increased mtDNA copy number during post-ovulatory aging of mouse oocytes. Bovine-oocyte work (Life Sciences 2025) extended this to cumulus-cell and blastocyst outcomes. These effects may reflect the 'non-canonical' cytoprotective functions of TERT (mitochondrial-membrane TERT is an established topic independent of Epitalon), but the causal chain from peptide to mitochondrial phenotype has not been fully dissected.
- 07
What is NOT known about the mechanism
No receptor or specific molecular binding partner for Epitalon has been identified outside the proposed DNA-promoter interaction model, and that model has not been validated by an independent structural study. Human pharmacokinetics — Cmax, Tmax, half-life, tissue distribution, CNS penetration, oral vs subcutaneous vs intranasal bioavailability — have not been published in peer-reviewed Western literature. The proposed 'epigenetic modulator' framing depends on Khavinson-group chromatin morphology methods rather than modern sequencing-based readouts. The oncologic implications of any telomerase or ALT activator in humans have not been studied under controlled conditions. Receptor pharmacology, human PK, and independent-lab mechanistic replication are the three missing pillars that prevent any outcome on this page from clearing the C/D boundary.